Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany

Open Access

Peer-reviewed

Research Article

Qing Qiao,

Affiliation AstraZeneca, Global Medicines Development, Mölndal, Sweden
⨯
Susan Grandy,

Affiliation AstraZeneca, Global Medicines Development, Gaithersburg, Maryland, United States of America
⨯
Josh Hiller,

Affiliation IMS Health, Real World Evidence Solutions, London, United Kingdom
⨯
Karel Kostev

* E-mail: kkostev@de.imshealth.com

Affiliation IMS Health, Epidemiology, Frankfurt am Main, Germany
⨯

Reader Comments (0)

Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
ACE inhibitor therapy
Is the Subject Area "ACE inhibitor therapy" applicable to this article?

Thanks for your feedback.
Primary care
Is the Subject Area "Primary care" applicable to this article?

Thanks for your feedback.
Health insurance
Is the Subject Area "Health insurance" applicable to this article?

Thanks for your feedback.
Obesity
Is the Subject Area "Obesity" applicable to this article?

Thanks for your feedback.
Germany
Is the Subject Area "Germany" applicable to this article?

Thanks for your feedback.
Insulin
Is the Subject Area "Insulin" applicable to this article?

Thanks for your feedback.